HK Stock Market Move | BAO PHARMA-B (02659) rose nearly 4% in the intraday trading session. The injection-grade human hyaluronidase KJ017 has been approved by the National Medical Products Administration for market launch.

BAO PHARMA-B (02659) rose nearly 4% during trading hours, and as of the time of publication, it had risen by 2.32% to HK$110.1, with a trading volume of HK$35.1469 million. On the news front, on April 8th, BAO PHARMA-B announced that its independently developed and leading injection-grade hyaluronidase in China (Boshuyi, project code KJ017), with a specification of 385U per bottle, has been approved for listing by the National Medical Products Administration. It is used to assist in subcutaneous infusion (such as sodium chloride injection and lactated Ringer's injection). KJ017 is a highly glycosylated recombinant human hyaluronidase that specifically breaks down hyaluronic acid in subcutaneous tissues, temporarily and locally increasing the permeability of the extracellular matrix of subcutaneous tissues. This enables safe, fast, high-volume subcutaneous administration, providing a new option for difficult-to-access patients for intravenous administration. Compared to traditional animal-derived hyaluronidase (which carries a risk of allergy, requiring a skin test before use, and with unstable quality between batches), KJ017 uses genetic recombination technology to achieve consistent quality between batches through controlled production processes, improving safety, significantly reducing the risk of immunogenicity, eliminating the need for skin testing before use, and enhancing the convenience and safety of clinical use.